Investors Don't See Light At End Of Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Tunnel And Push Stock Down 25%
Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares have had a horrible month, losing 25% after a relatively good period beforehand. Instead of being rewarded, shareholders who have already held through
Express News | Flagship Pioneering- $600 Mln in Payments From Novo Nordisk, to Be Shared Between Metaphore, Pioneering Medicines
Express News | Flagship Pioneering-Upto $600 Mln in Upfront, Development,Commercial Milestone Payments, Tiered Royalties on Annual Net Sales of Products From Novo
Express News | Flagship Pioneering Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
Foghorn Therapeutics | 10-Q: Quarterly report
Express News | Foghorn Therapeutics Inc. - Cash Runway Into First Half of 2026
Express News | Foghorn Therapeutics Q1 EPS USD -0.59
Express News | Foghorn Therapeutics Q1 Collaboration Revenue USD 5.05 Million
Express News | Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Express News | Foghorn Therapeutics Q1 Net Income USD -25.016 Million
Foghorn Therapeutics Cash, Cash Equivalents, and Marketable Securities of $206.7 M, as of March 31 >FHTX
Foghorn Therapeutics Cash, Cash Equivalents, and Marketable Securities of $206.7 M, as of March 31 >FHTX
Press Release: Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Foghorn(R) Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2024.
Analysts' Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53
Even though Foghorn Therapeutics Inc. (NASDAQ:FHTX) has fallen by 31% over the past week , insiders who sold US$72k worth of stock over the past year have had less luck.
Express News | Foghorn Therapeutics Has Appointed Kristian Humer As Chief Financial Officer
Express News | Foghorn Therapeutics Strengthens Financial Leadership With Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances
No Data